Info
Cambridge UK and Pleasanton USA-based biopharmaceutical company (formerly Astex Therapeutics, now Astex Pharmaceuticals, subsidiary of Otsuka). Pioneer of fragment-based drug discovery using high-throughput X-ray crystallography. The Astex fragment-screening platform was foundational for modern fragment-based methods now used at Diamond Light Source’s XChem and by the Structural Genomics Consortium.
Key Relationships
- Ian J. Tickle — senior crystallographer; XVTF member
- Contributor network to BUSTER-TNT refinement
- Fragment-based drug discovery community links to Frank von Delft / XChem at Diamond Light Source